Clinical-stage Leverage NeuroActiva is a clinical-stage biopharma focused on Alzheimer’s disease with NA-831 in Phase 2A and plans for later phases, signaling near-term regulatory milestones that can drive partnership or alliance opportunities with larger pharma seeking late-stage assets.

Neurology Portfolio Two drug candidates NA-831 and NA-704 address neurodegenerative targets including neuroprotection, neurogenesis, and cognitive restoration, presenting multiple entry points for collaborations, licensing, or co-development deals with institutions or biotech funds.

Innovative Delivery MICROS Infusion System enables controlled intravenous delivery of NA-704 for hospital and homecare settings, offering a differentiated product access path and potential integration into hospital systems, payer discussions, and end-user adoption strategies.

Strategic Parent As a wholly owned subsidiary of Biomed Industries, NeuroActiva may benefit from established distribution, regulatory, and funding channels, enabling accelerated business development conversations and potential synergistic deals with the parent company.

Market Readiness Current revenue under one million and a clear focus on Alzheimer’s therapeutics position NeuroActiva as an attractive target for niche-focused investors, contract development organizations, and early-access partnerships seeking to expand neurology portfolios.